Home
    Disclaimer
    MXM molecular structure

    MXM Stats & Data

    Mmxe Methoxmetamine 3-meo-2'-oxo-pcm
    NPS DataHub
    MW233.31
    FormulaC14H19NO2
    CAS1781829-56-8
    IUPAC2-(3-Methoxyphenyl)-2-(methylamino)cyclohexanone
    SMILESCOc1cccc(c1)C1(NC)CCCCC1=O
    InChIKeyZGQWDAOLJNAADS-UHFFFAOYSA-N
    Arylcyclohexylamines; 2021/6. Von Arylcyclohexylamin abgeleitete Verbindungen; 2022/6. Von Arylcyclohexylamin abgeleitete Verbindungen
    Psychoactive Class Dissociative
    Half-Life ~2–4 h (felt effects); human PK data absent—extrapolated by analogy within class

    Receptor Profile

    Receptor Actions

    Antagonists
    NMDA receptor antagonist (noncompetitive)
    Inhibitors
    Serotonin reuptake inhibitor

    Effect Profile

    Curated + 1 Reports
    Dissociative 6.0

    Strong dissociative depth and motor impairment with mild mania, low insight

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    4
    Insight / Novel Thought×2
    3
    Motor / Sensory Impairment×1
    10

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral / Sublingual
    30-45 minutes
    15-30 minutes
    30 minutes - 1.5 hours
    1-2 hours
    1-12 hours
    Total: 3-5 hours
    Insufflated
    4-15 minutes
    10-19 minutes
    30 minutes - 1.5 hours
    1-2 hours
    1-12 hours
    Total: 3-5 hours
    Intramuscular
    1-4 minutes
    4-15 minutes
    30 minutes - 1.5 hours
    1-2 hours
    1-12 hours
    Total: 3-5 hours
    Rectal
    10-19 minutes
    15-30 minutes
    30 minutes - 1.5 hours
    1-2 hours
    1-12 hours
    Total: 3-5 hours
    Oral
    3.0-5.0 hours
    2.0-4.0 hours
    Total: 3-5 hours

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    ~2–4 h (felt effects); human PK data absent—extrapolated by analogy within class
    Addiction Potential
    Moderate to high: short plateaus and notable euphoria can drive redosing; multiple forum reports describe compulsion and binges—plan doses in advance.

    Tolerance Decay

    Full tolerance 0h Half tolerance 4d Baseline ~14d

    Tolerance appears to increase rapidly after one strong session and decays over 1–2+ weeks, consistent with other arylcyclohexylamines; values are heuristic from user reports, not formal studies.

    Cross-Tolerances

    Ketamine
    60% ●○○
    MXE
    70% ●○○
    Other arylcyclohexylamines
    50% ●○○

    Experience Report Analysis

    Erowid
    1 Reports
    2015–2015 Date Range
    1 With Age Data

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Harm Reduction

    drugs.wiki

    - Naming and supply: MXM is widely discussed as 'Methoxmetamine' or simply 'MXM'; it has also been sold under confusing vendor labels like 'e-Methoxetamine'. Confusion with MXE and other 2-oxo arylcyclohexylamines has occurred; identity verification via reagent tests and, where available, GC/MS drug checking is strongly advised. In some markets, ketamine samples have been found to actually contain other arylcyclohexylamines (e.g., MXE), underscoring the value of checking.

    - ROA efficiency: Early reports consistently describe poor nasal efficacy and irritation with MXM; oral/sublingual routes produce more reliable effects for most users at comparable or lower totals.

    - Onset/plateau: Compared to MXE, MXM typically comes on faster and runs shorter (often ~2–3 h), which can encourage compulsive redosing—pre-weigh doses and set a firm maximum before starting.

    - Tolerance: Dissociative tolerance rises quickly, sometimes after a single strong session, and cross-tolerance with ketamine/MXE/other arylcyclohexylamines is expected. Allow long breaks (≥2 weeks) between sessions to reduce escalation.

    - Bladder/urinary risk: Like other dissociatives, repeated/frequent use is associated with urinary tract problems (urgency, frequency, pain). Stop use and seek medical evaluation if symptoms appear; spacing sessions and maintaining hydration may reduce risk.

    - Mental health: MXM can produce agitation or hypomanic qualities in some users; avoid if you have a history of psychosis or bipolar disorder, and do not combine with stimulants during/after high doses. Ensure a safe environment and sober support if experimenting with unfamiliar doses.

    - IM-specific HR: If choosing IM, use new sterile equipment, sterile water, proper site cleaning (single swipe with alcohol swab, let dry), rotate sites, and consider a 0.22–0.30 µm filter to reduce insoluble particles/endotoxin. Avoid IV due to very rapid onset and loss of motor control.

    - Driving and hazards: Severe impairment of coordination, balance and situational awareness occurs; plan not to drive or operate machinery for at least 24 hours after use.

    - Volumetric dosing and scales: Because redosing and impaired judgment are common on dissociatives, pre-measure doses with a 0.001 g scale; volumetric solutions can improve accuracy and reduce accidental heavy intakes.

    ← Back to MXM